Avadel Pharmaceuticals plc stock rating and score history
All changes in ratings, performance and outlook tracked over time.
Avadel Pharmaceuticals plc stock price, chart patterns and momentum
Recent price movements, trend behaviour and momentum signals based on real-time market data.
What does Avadel Pharmaceuticals plc do? Business model and key facts
Get the full picture of Avadel Pharmaceuticals plc: what it builds, where it operates, and how it makes money.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees (FY): 188
Avadel Pharmaceuticals plc is a biopharmaceutical firm primarily conducting its operations within the United States. The company's flagship investigational drug, FT218, a specialized compound of sodium oxybate, is currently in Phase 3 clinical trials. This therapeutic candidate aims to alleviate severe daytime somnolence and sudden muscle weakness (cataplexy) in adult individuals afflicted with narcolepsy. Established in 2015, the entity was formerly recognized as Flamel Technologies SA before rebranding as Avadel Pharmaceuticals plc in January 2017. Its global headquarters are situated in Dublin, Ireland.
Stocks related to Avadel Pharmaceuticals plc
Selected based on industry alignment and relative market positioning.
Events and news impacting Avadel Pharmaceuticals plc stock
Earnings, coporate decisions and industry developments that can affect the share price.
Avadel Pharmaceuticals plc fundamentals and technical analysis
Financial fundamentals and technicals signals combined to access stability, momentum and market direction.
